Microbial heparin/heparan sulphate lyases: Potential and applications

Applied Microbiology and Biotechnology

Volumn 94, Issue 2, 2012, Pages 307-321

  Tripathi, C K M ^a   Banga, Jaspreet ^a   Mishra, Vikas ^b  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Glycosaminoglycans; Heparin lyases; Low molecular weight heparins (LMWHs); Neovascularization; Unfractionated heparin (UFH)

Indexed keywords

GLYCOSAMINOGLYCANS; HEPARIN LYASES; LOW-MOLECULAR WEIGHT HEPARINS; NEOVASCULARIZATION; UNFRACTIONATED HEPARINS;

BIOCHEMISTRY; CELL MEMBRANES; COAGULATION; DEGRADATION; DISEASES; GLUCOSE; MOLECULAR WEIGHT; OLIGOSACCHARIDES; PATHOLOGY; POLYSACCHARIDES; SULFUR COMPOUNDS;

ENZYMES;

ARDEPARIN; BACTERIAL ENZYME; CERTIPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; HEPARAN SULPHATE GLYCOSAMINOGLYCAN; HEPARIN ANTAGONIST; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OLIGOSACCHARIDE; PARNAPARIN; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

ANTICOAGULANT; BIODEGRADATION; BLOOD; CELL ORGANELLE; COAGULATION; DRUG; LINEARITY; MAMMAL; MATRIX; MICROBIAL ACTIVITY; ORGANIC ACID; POLYMERIZATION; SULFATE; TUMOR;

ANTIANGIOGENIC ACTIVITY; BACILLUS; BACTEROIDES; BIOAVAILABILITY; CELL SURFACE; DEPOLYMERIZATION; DRUG SYNTHESIS; ENZYME DEGRADATION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; MOLECULAR WEIGHT; NONHUMAN; PEDOBACTER HEPARINUS; PROTEIN CLEAVAGE; REVIEW; SPHINGOBACTERIUM; VASCULARIZATION;

BACTERIA; FUNGI; HEPARIN; HEPARIN LYASE; HEPARITIN SULFATE; OLIGOSACCHARIDES;

MAMMALIA;

EID: 84862681683     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-3967-6     Document Type: Review

References (146)

1. Ammar T, Fisher CF (1997) The effects of heparinase I and protamine on platelet reactivity. Anesthesiology 86:1382-1386 (Pubitemid 27262317)
2. Ascencio F, Fransson LA, Wadstrom T (1993) Affinity of the gastric pathogen Helicobacter pylori for the N-sulphated glycosaminoglycan heparan sulphate. J Med Microbiol 38:240-244 (Pubitemid 23116352)
3. Baker E, Crawford J, Sutherland GR, Freeman C, Parish CR, Hulett MD (1999) Human HPA endoglycosidase heparanase. Map position 4q21.3. Chromosome Res 7:319 (Pubitemid 29353707)
4. Banga J, Tripathi CKM (2009) Rapid purification and characterization of a novel heparin degrading enzyme from Acinetobacter calcoaceticus. New Biotechnol 26:99-104
5. Banga J, Tripathi CKM (2010) Purification and characterization of a novel heparin degrading enzyme from Aspergillus flavus (MTCC8654). Appl Biochem Biotechnol 160:1004-1016
6. Bellamy R, Horikoshi K (1992) Heparinase produced by microorganism belonging to the genus Bacillus. US Patent 5,145,778
7. Benitz WE, Lessler DS, Coulson JD, Bernfield M (1986) Heparin inhibits proliferation of fetal vascular smooth muscle cells in the absence of platelet-derived growth factor. J Cell Physiol 127:1-7 (Pubitemid 16113478)
8. Bergqvist D (1996) Low molecular weight heparins. J Intern Med 240:63-72 (Pubitemid 26298127)
9. Bernard D, Mehul B, Delattre C, Simonetti L, Thomas-Collignon A, Schmidt R (2001) Purification and characterization of the endoglycosidase heparanase 1 from human plantar stratum corneum: a key enzyme in epidermal physiology? J Invest Dermatol 117:1266-1273 (Pubitemid 34205928)
10. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777 (Pubitemid 29449208)
11. Bikfalvi A, Javerzat S, Perollet C, Savona C (1997) Angiogenesis and cancer. Bull Cancer 84:885-890 (Pubitemid 27434218)
12. Bohmer LH, Pitout MJ, Allcock JL, Visser L (1990a) Heparin degradation by a novel microbial heparinase. Thromb Res 60:331-335
13. Bohmer LH, Pitout MJ, Steyn PL, Visser L (1990b) Purification and characterization of a novel heparinase. J Biol Chem 265:13609-13617
14. Bourin MC, Lindahl U (1993) Glycosaminoglycans and the regulation of blood coagulation. Biochem J 289(Pt 2):313-330 (Pubitemid 23042035)
15. Bugatti A, Urbinati C, Ravelli C, De Clercq E, Liekens S, Rusnati M (2007) Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother 51:2337-2345 (Pubitemid 47047308)
16. Castelli R, Porro F, Tarsia P (2004) The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9:205
17. Castellot JJ Jr, Favreau LV, Karnovsky MJ, Rosenberg RD (1982) Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem 257:11256-11260 (Pubitemid 13203358)
18. Castellot JJ Jr, Cochran DL, Karnovsky MJ (1985a) Effect of heparin on vascular smooth muscle cells. I. Cell metabolism. J Cell Physiol 124:21-28 (Pubitemid 15042634)
19. Castellot JJ Jr, Wong K, Herman B, Hoover RL, Albertini DF, Wright TC, Caleb BL, Karnovsky MJ (1985b) Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 124:13-20 (Pubitemid 15042633)
20. Casu B (2005) Structure and active domains of heparin. In: Garg HG, Linhardt RJ, Hales CA (eds) Chemistry and biology of heparin and heparan sulfate. Elsevier, London, pp 1-28
21. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3:866-871 (Pubitemid 27353446)
22. Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh VW (2000) Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60:6196-6200
23. Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H (2008) The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem 283:15193-15200
24. Dempsey LA, Brunn GJ, Platt JL (2000a) Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 25: 349-351 (Pubitemid 30497237)
25. Dempsey LA, Plummer TB, Coombes S, Platt JL (2000b) Platelet heparanase in vascular responses to xenotransplantation. Transplant Proc 32:972 (Pubitemid 30601833)
26. Dempsey LA, Plummer TB, Coombes SL, Platt JL (2000c) Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology 10:467-475 (Pubitemid 30216088)
27. Desai UR, Linhardt RJ (1994) Molecular-weight of low-molecularweight heparins by C-13 nuclear-magnetic-resonance spectroscopy. Carbohydr Res 255:193-212
28. Desai UR, Wang HM, Linhardt RJ (1993) Specificity studies on the heparin lyases from Flavobacterium heparinum. Biochemistry 32:8140-8145 (Pubitemid 23265801)
29. Dietrich CP, Nader HB (1974) Fractionation and properties of four heparitin sulfates from beef lung tissue. Isolation and partial characterization of a hemogeneous species of heparitin sulfate. Biochim Biophys Acta 343:34-44
30. Dietrich CP, Nader HB, Britto LR, Silva ME (1971) Chemical composition of heparitin sulfate. Fractionation and characterization of four acidic mucopolysaccharides in heparitin sulfate from beef lung tissue. Biochim Biophys Acta 237:430-441
31. Dietrich CP, Silva ME, Michelacci YM (1973) Sequential degradation of heparin in Flavobacterium heparinum. Purification and properties of five enzymes involved in heparin degradation. J Biol Chem 248:6408-6415
32. Dongfang L, Pojasek K, Shriver Z, Holley K, El-shabrawi Y, Venkataraman G, Sasisekharan R (2002) Heparinase III and uses thereof. EP Patent 1,266,013
33. Edens RE, al-Hakim A, Weiler JM, Rethwisch DG, Fareed J, Linhardt RJ (1992) Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J Pharm Sci 81:823-827 (Pubitemid 23006826)
34. Edens R, Linhardtb R, Weiler J (1993) Heparin is not just an anticoagulant anymore: six and one-half decades of studies on the ability of heparin to regulate complement activity. In: Cruise JM, Lewis RE (eds) Complement today. Karger, Basel, pp 96-120
35. Edens RE, LeBrun LA, Linhardt RJ, Kaul PR, Weiler JM (2001) Certain high molecular weight heparin chains have high affinity for vitronectin. Arch Biochem Biophys 391:278-285 (Pubitemid 32662270)
36. Engelberg H (1996) Actions of heparin in the atherosclerotic process. Pharmacol Rev 48:327-352 (Pubitemid 26196590)
37. Ernst S, Langer R, Cooney CL, Sasisekharan R (1995) Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol 30:387-444
38. Fairbanks MB, Mildner AM, Leone JW, Cavey GS, Mathews WR, Drong RF, Slightom JL, Bienkowski MJ, Smith CW, Bannow CA, Heinrikson RL (1999) Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 274:29587-29590
39. Fareed J, Hoppensteadt DA, Bick RL (2000) An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 26 (Suppl 1):5-21
40. Galliher PM, Cooney CL, Langer R, Linhardt RJ (1981) Heparinase production by Flavobacterium heparinum. Appl Environ Microbiol 41:360-365 (Pubitemid 11135582)
41. Galliher P, Linhardt R, Conway L, Langer R, Cooney C (1982) Regulation of heparinase synthesis in Flavobacterium heparinum. Appl Microbiol Biotechnol 15:252-257 (Pubitemid 13210996)
42. Gao N, Cheng X, Yang J, Zhang S (2003) Production of a novel heparinase from Sphingobacterium sp. Wei Sheng Wu Xue Bao 43:813-816
43. Gesner BM, Jenkin CR (1961) Production of heparinase by Bacteroides. J Bacteriol 81:595-604
44. Godavarti R, Sasisekharan R (1996) A comparative analysis of the primary sequences and characteristics of heparinases I, II, and III from Flavobacterium heparinum. Biochem Biophys Res Commun 229:770-777 (Pubitemid 27035794)
45. Godavarti R, Davis M, Venkataraman G, Cooney C, Langer R, Sasisekharan R (1996) Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Biochem Biophys Res Commun 225:751-758 (Pubitemid 26319178)
46. Gonzalez-Stawinski GV, Parker W, Holzknecht ZE, Huber NS, Platt JL (1999) Partial sequence of human platelet heparitinase and evidence of its ability to polymerize. Biochim Biophys Acta 1429:431-438 (Pubitemid 29065407)
47. Guo YC, Conrad HE (1988) Analysis of oligosaccharides from heparin by reversed-phase ion-pairing high-performance liquid chromatography. Anal Biochem 168:54-62 (Pubitemid 18088295)
48. Han C, Spring S, Lapidus A, Glavina Del Rio T, Tice H, Copeland A, Cheng JF, Lucas S, Chen F, Nolan M (2009) Complete genome sequence of Pedobacter heparinus type strain (HIM 762-3T). Stand Genomic Sci 1:54
49. Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC (2005) Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 11:8172-8179 (Pubitemid 41698761)
50. Heres EK, Horrow JC, Gravlee GP, Tardiff BE, Luber J Jr, Schneider J, Barragry T, Broughton R (2001) A dose-determining trial of heparinase-I (Neutralase) for heparin neutralization in coronary artery surgery. Anesth Analg 93:1446-1452 (Pubitemid 33111667)
51. Hileman RE, Smith AE, Toida T, Linhardt RJ (1997) Preparation and structure of heparin lyase-derived heparan sulfate oligosaccharides. Glycobiology 7:231-239 (Pubitemid 27168778)
52. Hook M, Bjork I, Hopwood J, Lindahl U (1976) Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 66:90-93
53. Hopwood JJ (1989) Enzymes that degrade heparin and heparan sulphate. In: Lane DW, Lindahl U (eds) Heparin: chemical and biological properties, clinical applications. Edward Arnold, London, pp 190-229
54. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5:803-809 (Pubitemid 29318615)
55. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR (2000) Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39:15659-15667 (Pubitemid 32038227)
56. Hyun YJ, Lee JH, Kim DH (2010) Cloning, overexpression, and characterization of recombinant heparinase III from Bacteroides stercoris HJ-15. Appl Microbiol Biotechnol 86:879-890
57. Jackson RL, Busch SJ, Cardin AD (1991) Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71:481-539
58. Kim DH, Kim BT, Park SY, Kim NY, Han MJ, Shin KH, Kim WS, Kim YS (1998) Degradation of acharan sulfate and heparin by Bacteroides stercoris HJ-15, a human intestinal bacterium. Arch Pharm Res 21:576-580 (Pubitemid 128668321)
59. Kim BT, Kim WS, Kim YS, Linhardt RJ, Kim DH (2000) Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15. J Biochem 128:323-328
60. Kim WS, Kim BT, Kim DH, Kim YS (2004) Purification and characterization of heparin lyase I from Bacteroides stercoris HJ-15. J Biochem Mol Biol 37:684-690 (Pubitemid 40221529)
61. Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P (1999) Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 261:183-187 (Pubitemid 29371638)
62. Langer RS, Linhardt RJ, Cooney CL, Fitzgerald G, Grant A (1983) Heparinase derived anticoagulants. US patent 4396762
63. Lantz M, Thysell H, Nilsson E, Olsson I (1991) On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 88:2026-2031
64. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N (2005) Identification and characterization of heparin/ heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 280:20457-20466 (Pubitemid 40776745)
65. Lindahl U, Backstrom G, Thunberg L, Leder IG (1980) Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A 77:6551-6555 (Pubitemid 11219166)
66. Linhardt RJ (1992) Chemical and enzymatic methods for the depolymerization and modification of heparin. In: Ogura H, Hasegawa A, Suami T (eds) Carbohydrates synthetic methods and applications in medicinal chemistry. Kodansha, Tokyo, pp 385-401
67. Linhardt RJ (1994) Analysis of glycosaminoglycans with polysaccharide lyases. In: Varki A (ed) Current protocols in molecular biology, analysis of glycoconjugates, 2008/02/12th edn. Wiley Interscience, Boston, pp 17.13.17-17.13.32
68. Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25(Suppl 3):5-16 (Pubitemid 29517028)
69. Linhardt RJ, Toida T (1997) Heparin oligosaccharides: new analogues development and applications. In: Witczak ZJ, Nieforth KA (eds) Carbohydrates in drug design. Marcel Dekker, New York, pp 277-341
70. Linhardt RJ, Cooney CL, Tapper D, Zannetos CA, Larsen AK, Langer R (1984) An immobilized microbial heparinase for blood deheparinization. Appl Biochem Biotechnol 9:41-55 (Pubitemid 14079409)
71. Linhardt RJ, Merchant ZM, Persinger DW (1985) Immuno-affinity purification of heparinase. Int J Biochem 17:1179-1183 (Pubitemid 16214607)
72. Linhardt RJ, Rice KG, Merchant ZM, Kim YS, Lohse DL (1986) Structure and activity of a unique heparin-derived hexasaccharide. J Biol Chem 261:14448-14454 (Pubitemid 17220227)
73. Linhardt RJ, Galliher PM, Cooney CL (1987) Polysaccharide lyases. Appl Biochem Biotechnol 12:135-176
74. Linhardt RJ, Gu KN, Loganathan D, Carter SR (1989) Analysis of glycosaminoglycan-derived oligosaccharides using reversed-phase ion-pairing and ion-exchange chromatography with suppressed conductivity detection. Anal Biochem 181:288-296 (Pubitemid 19230284)
75. Linhardt RJ, Turnbull JE, Wang HM, Loganathan D, Gallagher JT (1990) Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 29:2611-2617 (Pubitemid 20100860)
76. Linhardt RJ, Wang HM, Ampofo SA (1992) New methodologies in heparin structure analysis and the generation of LMW heparins. Adv Exp Med Biol 313:37-47
77. Linhardt R, Liu J, Han X (1993) Mapping and sequencing of oligosaccharides by electrophoresis. Trends Glycosci Glycotechnol 5:181-192
78. Linker A, Hovingh P (1965) The enzymatic degradation of heparin and heparitin sulfate: the fractionation of a crude heparinase from Flavobacteria. J Biol Chem 240:3724-3728
79. Loganathan D, Wang HM, Mallis LM, Linhardt RJ (1990) Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 29:4362-4368 (Pubitemid 20153637)
80. Lohse DL, Linhardt RJ (1992) Purification and characterization of heparin lyases from Flavobacterium heparinum. J Biol Chem 267:24347-24355
81. Mallis LM, Wang HM, Loganathan D, Linhardt RJ (1989) Sequence analysis of highly sulfated, heparin-derived oligosaccharides using fast atom bombardment mass spectrometry. Anal Chem 61:1453-1458 (Pubitemid 19187733)
82. McLean MW, F. LW, Williamson FR (1985) Proceeding of the VIIIth International Symposium on Glycoconjugates. Houston Paeger, New York
83. Michelsen LG, Kikura M, Levy JH, Lee MK, Lee KC, Zimmermann JJ, Szlam F (1996) Heparinase I (neutralase) reversal of systemic anticoagulation. Anesthesiology 85:339-346 (Pubitemid 26265235)
84. Mikhailov D, Mayo KH, Vlahov IR, Toida T, Pervin A, Linhardt RJ (1996) NMR solution conformation of heparin-derived tetrasaccharide. Biochem J 318(Pt 1):93-102 (Pubitemid 26283631)
85. Moffat CF, McLean MW, Long WF, Williamson FB (1991) Heparinase II from Flavobacterium heparinum. Action on chemically modified heparins. Eur J Biochem 197:449-459
86. Nader HB, Porcionatto MA, Tersariol IL, Pinhal MA, Oliveira FW, Moraes CT, Dietrich CP (1990) Purification and substrate specificity of heparitinase I and heparitinase II from Flavobacterium heparinum. Analyses of the heparin and heparan sulfate degradation products by 13C NMR spectroscopy. J Biol Chem 265: 16807-16813
87. Nakajima M, Irimura T, Nicolson GL (1986) Tumor metastasis-associated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells. Cancer Lett 31:277-283 (Pubitemid 16091018)
88. Nakamura T, Suginaka Y, Takazoe I (1976) Heparinase activity in lesion of periodontal diseases. Bull Tokyo Dent Coll 17:147-155
89. Nakamura T, Shibata Y, Fujimura S (1988) Purification and properties of Bacteroides heparinolyticus heparinase (heparin lyase, EC 4.2.2.7). J Clin Microbiol 26:1070-1071
90. Navarro FP, Fares RP, Sanchez PE, Nadam J, Georges B, Moulin C, Morales A, Pequignot JM, Bezin L (2008) Brain heparanase expression is up-regulated during postnatal development and hypoxiainduced neovascularization in adult rats. J Neurochem 105:34-45 (Pubitemid 351441630)
91. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP (1993) Heparin oligosaccharides bind L-and Pselectin and inhibit acute inflammation. Blood 82:3253-3258 (Pubitemid 23356692)
92. Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K (2002) Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 277:42488-42495 (Pubitemid 35285615)
93. Okuda K, Kato T, Shiozu J, Takazoe I, Nakamura T (1985) Bacteroides heparinolyticus sp. nov. isolated from humans with periodontitis. Int J Syst Evol Microbiol 35:438
94. Ototani N, Yosizawa Z (1978) Interaction of mucopolysaccharides with glycosaminoglycans on glycosaminoglycan-bound AH-Sepharose 4B. J Biochem 84:1005-1008 (Pubitemid 9057740)
95. Ototani N, Kikuchi M, Yosizawa Z (1981) Purification of heparinase and heparitinase by affinity chromatography on glycosaminoglycan bound AH-Sepharose 4B. Carbohydr Res 88:291-303
96. Pangrazzi J, Abbadini M, Zametta M, Naggi A, Torri G, Casu B, Donati MB (1985) Antithrombotic and bleeding effects of a low molecular weight heparin fraction. Biochem Pharmacol 34:3305-3308 (Pubitemid 16215694)
97. Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99-M108 (Pubitemid 32206686)
98. Petitou M, Casu B, Lindahl U (2003) 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 85:83-89
99. Pikas DS, Li JP, Vlodavsky I, Lindahl U (1998) Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 273:18770-18777 (Pubitemid 28366261)
100. Pluda JM (1997) Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203-218 (Pubitemid 27181127)
101. Raman K, Kuberan B (2010) Differential effects of heparitinase I and heparitinase III on endothelial tube formation in vitro. Biochem Biophys Res Commun 398:191-193
102. Reilly CF, Kindy MS, Brown KE, Rosenberg RD, Sonenshein GE (1989) Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem 264:6990-6995 (Pubitemid 19114815)
103. Rice KG, Rottink MK, Linhardt RJ (1987) Fractionation of heparin-derived oligosaccharides by gradient polyacrylamide-gel electrophoresis. Biochem J 244:515-522
104. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674 (Pubitemid 27193480)
105. Rosenberg RD (1989) Platelet heparitinase. Methods Enzymol 169:342-351 (Pubitemid 19101545)
106. Salyers AA, Vercellotti JR, West SE, Wilkins TD (1977) Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol 33:319-322 (Pubitemid 8099781)
107. Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12:89-98
108. Sasisekharan R, Bulmer M, Moremen KW, Cooney CL, Langer R (1993) Cloning and expression of heparinase I gene from Flavobacterium heparinum. Proc Natl Acad Sci USA 90:3660-3664 (Pubitemid 23111427)
109. Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer R (1994) Heparinase inhibits neovascularization. Proc Natl Acad Sci USA 91:1524-1528 (Pubitemid 24059045)
110. Sasisekharan R, Lohse D, Cooney C, Linhardt R, Langer R (1995) Purification of heparinase I, II, and III from Flavobacterium heparinum. United States Patent 5389539
111. Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer RS (1996a) Method for inhibiting angiogenesis using heparinase. US Patent 5567417
112. Sasisekharan R, Venkataraman G, Godavarti R, Ernst S, Cooney CL, Langer R (1996b) Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain. J Biol Chem 271:3124-3131 (Pubitemid 26055613)
113. Shaya D, Li Y, Cygler M (2004) Crystallization and preliminary X-ray analysis of heparinase II from Pedobacter heparinus. Acta Crystallogr D Biol Crystallogr 60:1644-1646 (Pubitemid 41103545)
114. Shaya D, Tocilj A, Li Y, Myette J, Venkataraman G, Sasisekharan R, Cygler M (2006) Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product. J Biol Chem 281:15525-15535 (Pubitemid 43855145)
115. Shenoy S, Harris RB, Sobel M (1999) Development of heparin antagonists with focused biological activity. Curr Pharm Des 5:965-986 (Pubitemid 30014006)
116. Shriver Z, Hu Y, Pojasek K, Sasisekharan R (1998a) Heparinase II from Flavobacterium heparinum. Role of cysteine in enzymatic activity as probed by chemical modification and site-directed mutagenesis. J Biol Chem 273:22904-22912 (Pubitemid 28417464)
117. Shriver Z, Hu Y, Sasisekharan R (1998b) Heparinase II from Flavobacterium heparinum. Role of histidine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis. J Biol Chem 273:10160-10167 (Pubitemid 28227615)
118. Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K, Sasisekharan R (2000) Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci USA 97:10365-10370
119. Silva ME, Dietrich CP (1974) Isolation and partial characterization of three induced enzymes from Flavobacterium heparinum involved in the degradation of heparin and heparitin sulfates. Biochem Biophys Res Commun 56:965-972
120. Silva M, Dietrich CP, Nader HB (1976) On the structure of heparitin sulfates. Analyses of the products formed from heparitin sulfates by two heparitinases and a heparinase from Flavobacterium heparinum. Biochim Biophys Acta 437:129-141
121. Silver PJ, Broughton R, Bouthillier J, Quinn TA, Wallace AM, Weishaar RE (1998) Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis. Thromb Res 91:143-150
122. Smith PN, Freeman C, Yu D, Chen M, Gatenby PA, Parish CR, Li RW (2010) Heparanase in primary human osteoblasts. J Orthop Res 28:1315-1322
123. Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoeft A, Dorenbaum A, Mathias J, Rochon JJ, Newman MF (2005) Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 103:229-240 (Pubitemid 41076719)
124. Stringer SE, Kandola BS, Pye DA, Gallagher JT (2003) Heparin sequencing. Glycobiology 13:97-107 (Pubitemid 36504019)
125. Su H, Blain F, Musil RA, Zimmermann JJ, Gu K, Bennett DC (1996) Isolation and expression in Escherichia coli of hepB and hepC, genes coding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum. Appl Environ Microbiol 62:2723-2734
126. Sugahara K, Tsuda H, Yoshida K, Yamada S, de Beer T, Vliegenthart JF (1995) Structure determination of the octa-and decasaccharide sequences isolated from the carbohydrate-protein linkage region of porcine intestinal heparin. J Biol Chem 270:22914-22923
127. Sundaram M, Venkataraman G, Shriver Z, Liu D, Qi Y, Sasisekharan R (2003) Methods and products related to low molecular weight heparin. EP Patent 1,319,183
128. Takahashi H, Matsumoto H, Kumon Y, Ohnishi T, Freeman C, Imai Y, Tanaka J (2007) Expression of heparanase in nestin-positive reactive astrocytes in ischemic lesions of rat brain after transient middle cerebral artery occlusion. Neurosci Lett 417:250-254 (Pubitemid 46613838)
129. Thanawiroon C, Linhardt RJ (2003) Separation of a complex mixture of heparin-derived oligosaccharides using reversed-phase high-performance liquid chromatography. J Chromatogr A 1014:215-223 (Pubitemid 37311173)
130. Timar J, Dome B, Fazekas K, Janovics A, Paku S (2001) Angiogenesisdependent diseases and angiogenesis therapy. Pathol Oncol Res 7:85-94
131. Toyoshima M, Nakajima M (1999) Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 274:24153-24160
132. Tumova S, Woods A, Couchman JR (2000) Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 32:269-288 (Pubitemid 30069970)
133. Urbinati C, Nicoli S, Giacca M, David G, Fiorentini S, Caruso A, Alfano M, Cassetta L, Presta M, Rusnati M (2009) HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 114:3335-3342
134. Venkataraman G, Shriver Z, Raman R, Sasisekharan R (1999) Sequencing complex polysaccharides. Science 286:537-542
135. Viskov C, Mourier P (2007) Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same. US patent 0,142,323
136. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5: 793-802 (Pubitemid 29318614)
137. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324:1-8
138. Yamada SH, Sugahara K (1998) Structure of oligosaccharides isolated from heparan sulfate heparin and substrate specificities of the degrading enzymes of bacterial origin. Trends Glycosci Glycotechnol 10:95-123 (Pubitemid 128607121)
139. Yang VC, Linhardt RJ, Bernstein H, Cooney CL, Langer R (1985) Purification and characterization of heparinase from Flavobacterium heparinum. J Biol Chem 260:1849-1857 (Pubitemid 15145468)
140. Yang VC, Bernstein H, Cooney CL, Langer R (1987) Large scale preparation and characterization of mucopolysaccharase contamination free heparinase. Appl Biochem Biotechnol 16:35-50
141. Yapeng C, Ningguo G, Xiulan C, Jing Y, Shijun Q, Shuzheng Z (2003) Rapid purification, characterization and substrate specificity of heparinase from a novel species of Sphingobacterium. J Biochem 134:365-371 (Pubitemid 37288335)
142. Yoshida E, Arakawa S, Matsunaga T, Toriumi S, Tokuyama S, Morikawa K, Tahara Y (2002a) Cloning, sequencing, and expression of the gene from Bacillus circulans that codes for a heparinase that degrades both heparin and heparan sulfate. Biosci Biotechnol Biochem 66:1873-1879 (Pubitemid 39246794)
143. Yoshida E, Sakai K, Tokuyama S, Miyazono H, Maruyama H, Morikawa K, Yoshida K, Tahara Y (2002b) Purification and characterization of heparinase that degrades both heparin and heparan sulfate from Bacillus circulans. Biosci Biotechnol Biochem 66:1181-1184 (Pubitemid 39251327)
144. Yu H, Munoz EM, Edens RE, Linhardt RJ (2005) Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta 1726:168-176 (Pubitemid 41572256)
145. Zhang F, Yoder PG, Linhardt RJ (2004) Synthetic and natural poly-saccharides with anticoagulant properties. In: Dumitriu S (ed) Polysaccharides: structural diversity and functional versatility, 2nd edn. Marcel Dekker, New York, pp 773-794
146. Zimmermann JJ, Oddie K, Langer R, Cooney CL (1991) The release of heparinase from the periplasmic space of Flavobacterium heparinum by three-step osmotic shock. Appl Biochem Biotechnol 30:137-148